<DOC>
	<DOCNO>NCT00599417</DOCNO>
	<brief_summary>Primary - To evaluate efficacy Pulmonaron decrease interleukin-4/interferon gamma second period treatment Secondary - To evaluate efficacy Pulmonarom prevention upper respiratory tract infection symptoms patient evaluation fever respiratory presence second period treatment - To evaluate loss work study day second period treatment - To evaluate safety tolerability Pulmonarom population study</brief_summary>
	<brief_title>PulmonarOM ( Bacterial Lysates ) Respiratory Tract Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Broncho-Vaxom</mesh_term>
	<criteria>Patients history relapse recurrence respiratory infection disease Patients chronic respiratory disease asthma , bronchitis sinusitis Patients unlikely comply protocol , example , uncooperativeness impossibility return followup visit Patients participate participate another clinical trial previous 3 month Patients receive immunology response stimulant previous 30 day Hypersensitivity The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>